The management of ductal carcinoma in situ is one of the most controversial areas in breast cancer management.
January 2018
With several new promising options, Jeffrey Zweig, MD, and Heather Wakelee, MD attempt to better answer the question of which ALK tyrosine kinase inhibitor (TKI) should be favored upfront.
Advertisement
Advertisement
Trending on OncLive
1
Dr Mesa on the FDA Approval of Ropeginterferon Alfa-2b for Essential Thrombocythemia
2
TTFields Add a New Dimension to the Changing Pancreatic Cancer Treatment Paradigm
3
Zanidatamab Plus Chemotherapy Improves OS at Second Interim Analysis of HERIZON-GEA-01 in First-Line HER2+ GEA
4
Savolitinib Plus Osimertinib Improves First-Line PFS in MET-Overexpressing EGFR-Mutated NSCLC
5